Renosart Plus Tablet
Hydrochlorothiazide + Losartan Potassium
12.5mg + 50mg
Leon Pharmaceuticals Ltd.
Pack size | |
---|---|
Unite Price | 8.02 BDT |
Indications
Renosart Plus Tablet is used for:
Hypertension, Stroke, risk reduction of hypertensive or LVH patients
Adult Dose
Hypertension
Initial: 50 mg/12.5 mg PO qDay
If dose titrated upward, do not to exceed final titration of 100 mg/25 mg PO qDay or 50 mg/12.5 mg PO q12hr
Decrease losartan to 25 mg PO qDay initially if volume depleted
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
CrCl <30 mL/min: Do not use thiazide-containing products; loop diuretic preferred
CrCl >30 mL/min: No dosage adjustment required
Administration
Contra Indications
Pregnancy, lactation; intravascular volume depletion.
Precautions
Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
Lactation: Discontinue drug or do not nurse
Pregnancy-Lactation
Pregnancy
Therapy can cause fetal harm when administered to a pregnant woman; use of drugs that act on renin-angiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in first trimester have not distinguished drugs affecting renin-angiotensin system from other antihypertensive agents; when pregnancy is detected, discontinue therapy as soon as possible
Hypertension in pregnancy increases maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (eg, need for cesarean section, post-partum hemorrhage)
Hypertension increases fetal risk for intrauterine growth restriction and intrauterine death; pregnant women with hypertension should be carefully monitored and managed accordingly
Fetal/neonatal adverse reactions
Losartan
Use of drugs that act on the renin-angiotensin system in second and third trimesters of pregnancy can result in oligohydramnios, reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin- angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus
Perform serial ultrasound examinations to assess the intra-amniotic environment; if oligohydramnios is observed, discontinue therapy, unless it is considered lifesaving for the mother
Fetal testing may be appropriate, based on week of gestation
Patients and physicians should be aware, however, that oligohydramnios may not appear until after fetus has sustained irreversible injury; closely observe neonates with histories of in utero exposure to drug combination for hypotension, oliguria, and hyperkalemia
In neonates with a history of in utero exposure to drug combination, if oliguria or hypotension occurs, support blood pressure and renal perfusion
Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function
Hydrochlorothiazide
Thiazides can cross placenta, and concentrations reached in umbilical vein approach those in maternal plasma
Like other diuretics, the drug can cause placental hypoperfusion; it accumulates in amniotic fluid, with reported concentrations up to 19 times higher than in umbilical vein plasma
Use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice or thrombocytopenia
Since they do not alter the course of preeclampsia, these drugs should not be used to treat hypertension in pregnant women
The use of hydrochlorothiazide for other indications in pregnancy should be avoided
Lactation
Not known whether losartan is excreted in human milk, but significant levels of losartan and its active metabolite were shown to be present in rat milk; thiazides appear in human milk; because of potential for adverse effects on nursing infant, a decision should be made whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother
Interactions
Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment.
Losartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K.
Hydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
Side Effects
Side effects of Hydrochlorothiazide + Losartan Potassium :
>10%
Losartan
Fatigue (14%), Hypoglycemia (14%), Chest pain (12%), Cough, incidence higher in previous cough related to ACE therapy (3-11%)
1-10%
Losartan
Diarrhea (2-10%), URI (8%), Hypotension (7%), Dizziness (4%), Nausea (2%)
Hydrochlorothiazide
Hypotension, Anorexia, Epigastric distress, Hypokalemia, Phototoxicity, Thrombocytopenia
Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
Mode of Action
Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
Note
Renosart Plus 12.5mg + 50mg Tablet generic name is Hydrochlorothiazide + Losartan Potassium. Renosart Plus 12.5mg + 50mg Tablet is manufactured by Leon Pharmaceuticals Ltd.Renosart Plus is availble in all over Bangladesh.
Mes BD drug index information on Renosart Plus Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Hydrochlorothiazide + Losartan Potassium :
Tablet
Acusan Plus
12.5mg + 50mg
Concord Pharmaceuticals Ltd.
Tablet
Angilock PLUS
12.5mg + 100mg
Square Pharmaceuticals Ltd.
Tablet
Angilock PLUS
25mg + 100mg
Square Pharmaceuticals Ltd.
Tablet
Anin 50 Plus
12.5mg + 50mg
Delta Pharma Limited
Tablet
Anreb PLUS
12.5 mg + 50 mg
General Pharmaceuticals Ltd.